EuroBiotech: More Articles of Note


> SurgiMab moved SGM-101 into phase 3 studies. SGM-101 is a tumor-specific antibody designed for use in colorectal cancer surgery. Release 

> Oryzon published data from a phase 2a Alzheimer’s disease clinical trial. The update showed some of the first 33 patients to complete 24 weeks of follow-up had stable or improving disease. Statement 

> Mereo BioPharma detailed plans to win accelerated approval of navicixizumab on the strength of a phase 2 trial. The disclosure follows a meeting between Mereo and the FDA about the ovarian cancer drug. Release 


How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

> Motif Bio filed a meeting request and data related to its antibiotic iclaprim with the FDA. The filing follows indications from the FDA that Motif will need to run another trial to win approval. Statement 

> AC Immune moved its Eli Lilly-partnered tau drug into phase 1. The trial will assess the safety and other features of the drug in healthy volunteers. Release 

> NuCana dosed the first patient in a phase 1 trial of its cordycepin-derived drug. The trial will enroll up to 61 solid tumor patients. Statement 

Suggested Articles

Horizon Therapeutics is expanding its U.S. footprint to the Bay Area—the company unveiled a new R&D and manufacturing site in South San Francisco.

Azeria Therapeutics has raised £32 million ($41 million) to take its estrogen receptor positive breast cancer program into the clinic.

Biogen’s Al Sandrock has given a bullish assessment of Alzheimer’s disease drug aducanumab. The head of R&D at Biogen thinks the drug works, despite i